BiOPartnering Platform Opens Tomorrow – Only Five Meeting Rooms Remaining for BIOCHINA 2026

BIOCHINA 2026 is just two months away, taking place from March 12–14, 2026, in Suzhou. The highly anticipated BiOPartnering platform will officially open tomorrow, giving participants the chance to schedule one-on-one meetings with leading global pharmaceutical and biotech decision-makers.

The demand is already unprecedented. As of January 13, only five BiOPartnering rooms remain available, offering a rare opportunity for direct engagement with top industry players. Confirmed participants include multinational corporations such as Bayer, Pfizer, Eli Lilly, Novartis, and Novo Nordisk, global pharma and business organizations like Sun Pharma, Dr. Reddy’s, Hikma, Asahi Kasei, the Canadian Trade Office, George Medicines, and Syneos Health, as well as leading Chinese innovative pharma companies including Gan & Lee Pharma, Enno Pharma, and Qide Pharma.

The BiOPartnering platform provides unmatched opportunities to:

• Conduct face-to-face meetings with senior executives from global pharma and biotech companies
• Explore strategic collaborations with active investors
• Unlock new licensing, M&A, and innovation opportunities in China’s biopharmaceutical sector

With the platform opening tomorrow, participants can immediately start booking meetings and maximizing their networking potential ahead of the exhibition. BIOCHINA 2026 remains the premier destination for business development, licensing, and cross-border collaboration in the global biopharma community.

Register now to secure your spot and schedule your one-on-one meetings:

Register: https://lnkd.in/giDCUTYr

Learn More: https://lnkd.in/gv3JpqWY

For consultation on the agenda, full participant list, visa support, or one-on-one guidance: WhatsApp +86 156 1892 1630 | Email: biochina@enmore.com